Literature DB >> 25653825

Reducing the rates of prescribing high-dose antipsychotics and polypharmacy on psychiatric inpatient and intensive care units: results of a 6-year quality improvement programme.

Shubhra Mace1, David Taylor2.   

Abstract

BACKGROUND: There is no conclusive evidence that either high doses or combinations of antipsychotics are more effective than standard doses or monotherapy alone. Nonetheless, prescription of both remains prevalent in the UK. In 2006 the South London and Maudsley NHS Foundation Trust (SLAM) participated in a national survey of prescription of antipsychotic medications, organized by the Prescribing Observatory for Mental Health. Over half of the patients on SLAM inpatient or psychiatric intensive care units were prescribed a high-dose antipsychotic or a combination of antipsychotics. Prescribing high-dose antipsychotics and polypharmacy in SLAM was found to be among the highest in the UK. AIM: To assess the impact of a 6-year quality improvement programme aimed at reducing the rates of prescribing high-dose antipsychotics and polypharmacy on SLAM inpatients and psychiatric intensive care units.
RESULTS: There was a significant reduction between baseline and final survey in the rates of prescription of both high-dose antipsychotics and polypharmacy on SLAM inpatients and intensive care units (58% versus 10% p < 0.0001 and 57% versus 16%, p < 0.0001 respectively). The proportion of patients at final survey prescribed a high-dose antipsychotic and a combination was substantially lower in SLAM than in the national sample (10% versus 28%, p < 0.0001 and 16% versus 38%, p < 0.0001 respectively). CLINICAL IMPLICATIONS: A sustained change in the prescribing culture of an organization can be achieved through a targeted improvement programme.

Entities:  

Keywords:  antipsychotic; high dose; polypharmacy; prescribing; quality improvement

Year:  2015        PMID: 25653825      PMCID: PMC4315670          DOI: 10.1177/2045125314558054

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  33 in total

1.  Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial.

Authors:  W Wolfgang Fleischhacker; Martti E Heikkinen; Jean-Pierre Olié; Wally Landsberg; Patricia Dewaele; Robert D McQuade; Jean-Yves Loze; Delphine Hennicken; Wendy Kerselaers
Journal:  Int J Neuropsychopharmacol       Date:  2010-05-12       Impact factor: 5.176

2.  Does antipsychotic polypharmacy increase the risk for metabolic syndrome?

Authors:  Christoph U Correll; Anne M Frederickson; John M Kane; Peter Manu
Journal:  Schizophr Res       Date:  2006-10-27       Impact factor: 4.939

Review 3.  Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses.

Authors:  R J Baldessarini; B M Cohen; M H Teicher
Journal:  Arch Gen Psychiatry       Date:  1988-01

Review 4.  Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness.

Authors:  Marc W H Lochmann van Bennekom; Harm J Gijsman; Frans G Zitman
Journal:  J Psychopharmacol       Date:  2013-02-14       Impact factor: 4.153

5.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

Review 6.  Antipsychotic polypharmacy in schizophrenia: benefits and risks.

Authors:  Thomas R E Barnes; Carol Paton
Journal:  CNS Drugs       Date:  2011-05       Impact factor: 5.749

7.  Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study.

Authors:  Bruce J Kinon; Jan Volavka; Virginia Stauffer; Sara E Edwards; Hong Liu-Seifert; Lei Chen; David H Adams; Jean-Pierre Lindenmayer; Joseph P McEvoy; Peter F Buckley; Jeffrey A Lieberman; Herbert Y Meltzer; Daniel R Wilson; Leslie Citrome
Journal:  J Clin Psychopharmacol       Date:  2008-08       Impact factor: 3.153

Review 8.  'As required' medication regimens for seriously mentally ill people in hospital.

Authors:  E Whicher; M Morrison; P Douglas-Hall
Journal:  Cochrane Database Syst Rev       Date:  2002

9.  High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing.

Authors:  Carol Paton; Thomas R E Barnes; Mary-Rose Cavanagh; David Taylor; Paul Lelliott
Journal:  Br J Psychiatry       Date:  2008-06       Impact factor: 9.319

Review 10.  Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder.

Authors:  Shubhra Mace; David Taylor
Journal:  CNS Drugs       Date:  2009-09       Impact factor: 5.749

View more
  9 in total

1.  Factors associated with non evidence-based prescribing of antipsychotics.

Authors:  Anne Connolly; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2014-12

2.  Antipsychotic polypharmacy prescribing and risk of hospital readmission.

Authors:  Giouliana Kadra; Robert Stewart; Hitesh Shetty; James H MacCabe; Chin-Kuo Chang; Jad Kesserwani; David Taylor; Richard D Hayes
Journal:  Psychopharmacology (Berl)       Date:  2017-10-28       Impact factor: 4.530

3.  Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points.

Authors:  Sara S McMillan; Sara Jacobs; Louise Wilson; Theo Theodoros; Gail Robinson; Claire Anderson; Gabor Mihala; Amanda J Wheeler
Journal:  BMC Psychiatry       Date:  2017-04-13       Impact factor: 3.630

4.  Long-term antipsychotic polypharmacy prescribing in secondary mental health care and the risk of mortality.

Authors:  G Kadra; R Stewart; H Shetty; J H MacCabe; C-K Chang; D Taylor; R D Hayes
Journal:  Acta Psychiatr Scand       Date:  2018-05-29       Impact factor: 6.392

5.  Predicting parkinsonism side-effects of antipsychotic polypharmacy prescribed in secondary mental healthcare.

Authors:  Giouliana Kadra; Athan Spiros; Hitesh Shetty; Ehtesham Iqbal; Richard D Hayes; Robert Stewart; Hugo Geerts
Journal:  J Psychopharmacol       Date:  2018-09-20       Impact factor: 4.153

6.  Implementation of a clinical practice guideline for schizophrenia in a specialist mental health center: an observational study.

Authors:  Ilan Fischler; Sanaz Riahi; Melanie I Stuckey; Philip E Klassen
Journal:  BMC Health Serv Res       Date:  2016-08-11       Impact factor: 2.655

7.  Predictors of long-term (≥6months) antipsychotic polypharmacy prescribing in secondary mental healthcare.

Authors:  Giouliana Kadra; Robert Stewart; Hitesh Shetty; Johnny Downs; James H MacCabe; David Taylor; Richard D Hayes
Journal:  Schizophr Res       Date:  2016-04-16       Impact factor: 4.939

8.  Risk Factors of Metabolic Syndrome Among Patients Receiving Antipsychotics: A Retrospective Study.

Authors:  Samer Hammoudeh; Hawra Al Lawati; Suhaila Ghuloum; Huma Iram; Arij Yehya; Imen Becetti; Nora Al-Fakhri; Hany Ghabrash; Mena Shehata; Nighat Ajmal; Iman Amro; Hira Safdar; Yassin Eltorki; Hassen Al-Amin
Journal:  Community Ment Health J       Date:  2019-12-28

9.  Drug-naïve first-episode schizophrenia spectrum disorders: Pharmacological treatment practices in inpatient units in Hunan Province, China.

Authors:  Mengran Zhu; Maria Ferrara; Wenjian Tan; Xingbo Shang; Sumaiyah Syed; Li Zhang; Qilin Qin; Xinran Hu; Robert Rohrbaugh; Vinod H Srihari; Zhening Liu
Journal:  Early Interv Psychiatry       Date:  2020-09-14       Impact factor: 2.732

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.